Abbott has reported that its continuous glucose monitoring (CGM) system FreeStyle Libre significantly minimised haemoglobin A1c (HbA1c) levels in type 2 diabetes patients on intensive insulin therapy.
The data has been obtained through combined analysis of three separate retrospective, real-world studies that assessed the FreeStyle Libre system’s impact on glycaemic control.
During the analysis, records of 363 subjects across France, Germany and Austria were examined for their HbA1c levels over three to six months. This involved people aged an average of 63 years needing insulin multiple times a day for an average of more than eight years.
After at least three months of use, approximately 1% HbA1c reduction was observed, indicating a significant decrease in glucose levels, said Abbott.
In addition, data revealed 8% average HbA1c with FreeStyle Libre use, compared to 8.9% before use of the system.
Investigators reported no differences depending on age group, gender, body mass index or duration of insulin use. According to Abbott, this suggests that the results apply to a wide type 2 diabetes population.
Abbott Diabetes Care global medical and scientific affairs divisional vice-president Mahmood Kazemi said: “Doctors tell us that FreeStyle Libre is changing the course of care for people with diabetes, and the combination of these real-world data and clinical research is further proof that our technology delivers significant reductions in HbA1c in people with type 2 diabetes.
“This adds to growing evidence from more than half a million users in real-world settings showing time after time, use of FreeStyle Libre is associated with improved glucose control and better health outcomes.”
The FreeStyle Libre Flash Glucose Monitoring system is indicated to replace blood glucose monitoring and does not require the standard finger sticks or their calibration.
It identifies trends and patterns to help detect hyperglycemia and hypoglycaemia episodes, in turn allowing therapy adjustments in diabetes patients.
Currently, the device is used by more than 1.5 million people living with diabetes across 46 countries.